All-In with Chamath, Jason, Sacks & Friedberg E35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, real estate, Bitcoin & more
Jun 13, 2021
Dive into the heated debate over Biogen's controversial Alzheimer's drug approval and its implications for healthcare. Explore the thrilling billionaire space race, questioning the motivations behind these cosmic ambitions. The hosts tackle the challenges of workplace dynamics in a post-pandemic world and reveal the impact of inflation on the housing market. Discuss the widening wealth gap and the complexities of taxation for the ultra-wealthy. Finally, enjoy a light-hearted exploration of nuclear energy myths and the whimsical notions of cloning.
AI Snips
Chapters
Transcript
Episode notes
Controversial Alzheimer's Drug Approval
- Biogen's Alzheimer's drug, Aduhelm, received FDA approval despite an advisory panel's unanimous rejection.
- Three panel members resigned, highlighting the controversy surrounding the drug's modest efficacy and high cost.
Ethical Drug Pricing
- Approving drugs with low efficacy and high costs raises ethical and financial concerns.
- How do we balance patient hope with the financial burden on payers?
Alzheimer's Impact and Investment Risks
- Alzheimer's disproportionately affects minorities and women, making it a critical health equity issue.
- Previous Alzheimer's drug trials have failed, leading to infamous insider trading events.